Cannabis
Cannassure Completes Their Medical Cannabis Analytical Method Development and Validation in Accordance With the Israeli Medical Cannabis Agency (IMCA) Requirements
Cannassure Therapeutics (TASE: CSURE) announces another company milestone as they successfully complete their medical cannabis analytical method development and validation, in accordance with IMCA requirements. The activity was conducted in the company’s laboratory, led by Dana Marom, VP QA, and performed by the highly skilled Cannassure R&D and QA teams, accompanied by a GSAP regulatory consulting team.
The analysis and validation methods developed, identify seven cannabinoids-THC and CBD and their derivatives THCA and CBDA, as well as CBN, CBC and CBG. The cannabinoids can be detected in cannabis flowers, extracts, and tinctures to ensure quality, stability and consistency of Cannassure’s products and meet GMP and other regulatory requirements and specifications for the pharmaceutical industry.
“Cannassure has the knowhow to conduct our own testing of cannabis and medical cannabis products in a fast and reliable manner, without the need of external suppliers. This is completely in line with the company’s strategy of establishing a holistic medical cannabis production facility. Our vertically integrated operation will include advanced agritech breeding, an indoor grow operation, a state-of-the-art extraction and processing facility, together with scientifically advanced R&D,” states Ran Amir, Cannassure CEO.
SOURCE Cannassure Therapeutics
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis4 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE5 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Humboldt4 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis4 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 days ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III